AVALO THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AVALO THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $404.91M.
- AVALO THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-12-31 was -$70.00K.
- AVALO THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $14.37M.
- AVALO THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $14.30M.
- AVALO THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $32.47M.
- AVALO THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2020 was $35.43M, a 294.70% increase from fiscal 2019.
- AVALO THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2019 was $8.98M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $404.91M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | -$70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $14.30M 10-K · filed 2026-03-23 |
| 2025-09-30 | $14.37M 10-Q · filed 2025-11-06 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $32.47M 10-K · filed 2025-03-20 |
| 2023-09-30 | $25.94M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $6.53M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $13.75M 10-Q · filed 2023-05-04 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $37.65M derived: sum of 4 quarters · filed 2022-03-02 |
| 2021-03-31 | $37.65M 10-Q · filed 2021-05-13 | $73.08M derived: sum of 4 quarters · filed 2022-03-02 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $35.43M 10-K · filed 2022-03-02 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | |
| 2020-06-30 | $35.43M 10-Q · filed 2021-08-02 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $8.98M 10-K · filed 2021-03-08 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $8.98M derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $8.98M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $8.98M 10-Q · filed 2019-05-09 | $8.98M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $0.00 10-K · filed 2019-03-18 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 | |
| 2017-12-31 | $1.50M 10-K · filed 2019-03-18 | |
| 2016-12-31 | $1.90M 10-K · filed 2018-04-02 | |
| 2015-12-31 | $21.17M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |